This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hong, R.-L. Articles by Lui, L. T. Search for Related Content PubMed PubMed Citation Articles by Hong, R.-L. Articles by Lui, L. T. Social Bookmarking                            What's this?

Induction Chemotherapy With Mitomycin, Epirubicin, Cisplatin, Fluorouracil, and Leucovorin Followed by Radiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma

From the Departments of Oncology, Otolaryngology, and Radiation Therapy, National Taiwan University Hospital, National Taiwan University; and National Taiwan University Hospital Cooperative Ward, Division of Cancer Research, National Health Research Institute, Taipei, Taiwan.

Address reprint requests to Ruey-Long Hong, MD, PhD, Department of Oncology, National Taiwan University Hospital, National Taiwan University, No 7, Chung-Shan South Rd, Taipei 10016, Taiwan; email: rlhong{at}ha.mc.ntu.edu.tw

PURPOSE: Survival in advanced nasopharyngeal carcinoma (NPC) is compromised by distant metastasis. Because mitomycin is active against hypoxic and G0 cells, which may help to eradicate micrometastasis, we investigated the effect of mitomycin-containing cisplatin-based induction chemotherapy.

PATIENTS AND METHODS: Recruited for this study were American Joint Committee on Cancer (AJCC) 1992 staging system stage IV NPC patients with the following adverse features: obvious intracranial invasion, supraclavicular or bilateral neck lymph node metastasis, large neck node (> 6 cm), or elevated serum lactate dehydrogenase (LDH) level. Patients were given three cycles of chemotherapy before radiotherapy. The chemotherapy comprised a 3-week cycle of mitomycin, epirubicin, and cisplatin on day 1 and fluorouracil and leucovorin on day 8 (MEPFL).

RESULTS: From January 1994 to December 1997, 111 patients were recruited. The median follow-up period was 43 months. The actuarial 5-year overall survival rate was 70% (95% confidence interval [CI], 60% to 80%; n = 111). For patients having completed radiotherapy (n = 100), the 5-year locoregional control rate was 70% (95% CI, 55% to 84%) and the distant metastasis–free rate was 81% (95% CI, 73% to 89%). The 5-year distant metastasis–free rate of N3a and N3b disease of AJCC 1997 staging system were 79% (95% CI, 62% to 95%) and 74% (95% CI, 60% to 89%), respectively. By Cox multivariate analysis, high pretreatment serum LDH level (P = .04) and neck nodal enlargement before radiotherapy (P = .001) were adverse prognostic factors of survival.

CONCLUSION: The good 5-year survival of N3 disease supports the effectiveness of induction MEPFL in the primary treatment of advanced NPC. Further investigation to incorporate concurrent chemoradiotherapy is warranted.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. T.T. Chua, J. Ma, J. S.T. Sham, H.-Q. Mai, D. T.K. Choy, M.-H. Hong, T.-X. Lu, and H.-Q. Min Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III Trials J. Clin. Oncol., February 20, 2005; 23(6): 1118 - 1124. [Abstract] [Full Text] [PDF]

				T. P. Farias, F. L. Dias, R. A. Lima, J. Kligerman, G. M. de Sa, M. M. Barbosa, and F. B. Goncalves Jr Prognostic Factors and Outcome for Nasopharyngeal Carcinoma Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 794 - 799. [Abstract] [Full Text] [PDF]

				J.-C. Lin, J.-S. Jan, C.-Y. Hsu, W.-M. Liang, R.-S. Jiang, and W.-Y. Wang Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression-Free Survival J. Clin. Oncol., February 15, 2003; 21(4): 631 - 637. [Abstract] [Full Text] [PDF]